期刊文献+

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients 被引量:8

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
下载PDF
导出
摘要 AIM: To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD).METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6 -month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events.RESULTS: At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72 ±0.23 and 0.73 ±0.22 to 0.47 ±0.14 and 0.45 ±0.20, respectively (P 【0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71 ±34.72μm and 352 ±36.9μm at baseline to 250.86 ± 41.51μm and 243.22 ±41.38μm in the bevacizumab and ranibizumab groups, respectively (P 【0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events.CONCLUSION:Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term. AIM: To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD).METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6 -month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events.RESULTS: At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72 ±0.23 and 0.73 ±0.22 to 0.47 ±0.14 and 0.45 ±0.20, respectively (P <0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71 ±34.72μm and 352 ±36.9μm at baseline to 250.86 ± 41.51μm and 243.22 ±41.38μm in the bevacizumab and ranibizumab groups, respectively (P <0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events.CONCLUSION:Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.
出处 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2013年第2期169-173,共5页 国际眼科杂志(英文版)
关键词 age-related macular degeneration choroidal neovascularization bevacizumab (avastin) ranibizumab (lucentis) age-related macular degeneration choroidal neovascularization bevacizumab (avastin) ranibizumab (lucentis)
  • 相关文献

参考文献16

  • 1Jan S. A. G. Schouten,Ellen C. Heij,Carroll A. B. Webers,Igor J. Lundqvist,Fred Hendrikse.A systematic review on the effect of bevacizumab in exudative age-related macular degeneration[J]. Graefe’s Archive for Clinical and Experimental Ophthalmology . 2009 (1)
  • 2Martin DF,Maguire MG,Fine SL,Ying GS,Jaffe GJ,Grunwald JE,Toth C,Redford M,Ferris FL 3rd.Ranibizumab and bevacizumab for treatment of neovascular age - related macular degeneration: two - year results. Ophthalmology . 2012
  • 3HeraR,KeramidasM,Peoc‘hM,MouillonM,RomanetJP,FeigeJJ.Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. American Journal of Ophthalmology . 2005
  • 4Tatar O,Adam A,Shinoda K, et al.Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. American Journal of Ophthalmology . 2006
  • 5J Raftery,A Clegg,J Jones,SC Tan,A Lotery.Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. British Journal of Ophthalmology . 2007
  • 6Zou HD,Zhang X,Xu X,Wang FH,Zhang SJ.Age-related macular degeneration prevalence survey of Caojiadu street Jing’’an district in Shanghai. ZhonghuaYanke Zhazhi . 2005
  • 7Ni Z.Pathological anatomy and clinical of ophthalmology. . 2002
  • 8Sheng YJ.Advances in the treatment of age-related macular degeneration. Journal of Clinical Psychopharmacology . 2004
  • 9Bressler NM.Antiangiogenic approaches to aged-related macular degeneration today. Ophthalmology . 2009
  • 10Chakravarthy U,Harding SP,Rogers CA,Downes SM,Lotery AJ,Wordsworth S,Reeves BC.Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology . 2012

同被引文献16

引证文献8

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部